MA46524A - Composés de biphényl-sulfonamide destinés au traitement de néphropathies - Google Patents

Composés de biphényl-sulfonamide destinés au traitement de néphropathies

Info

Publication number
MA46524A
MA46524A MA046524A MA46524A MA46524A MA 46524 A MA46524 A MA 46524A MA 046524 A MA046524 A MA 046524A MA 46524 A MA46524 A MA 46524A MA 46524 A MA46524 A MA 46524A
Authority
MA
Morocco
Prior art keywords
nephropathies
biphenyl
treatment
sulfonamide compounds
sulfonamide
Prior art date
Application number
MA046524A
Other languages
English (en)
Inventor
Radko Komers
Alvin Shih
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Publication of MA46524A publication Critical patent/MA46524A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046524A 2016-10-13 2017-10-13 Composés de biphényl-sulfonamide destinés au traitement de néphropathies MA46524A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US201662423079P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
MA46524A true MA46524A (fr) 2019-08-21

Family

ID=60191503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046524A MA46524A (fr) 2016-10-13 2017-10-13 Composés de biphényl-sulfonamide destinés au traitement de néphropathies

Country Status (10)

Country Link
US (5) US20190262317A1 (fr)
EP (1) EP3525784B1 (fr)
JP (4) JP2019530713A (fr)
KR (4) KR20240162167A (fr)
CN (5) CN117017985A (fr)
AU (3) AU2017341825B2 (fr)
BR (1) BR112019007576A2 (fr)
CA (1) CA3039819A1 (fr)
MA (1) MA46524A (fr)
WO (1) WO2018071784A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102902972B1 (ko) 2018-10-04 2025-12-22 트래버르 테라퓨틱스, 인코포레이티드 Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
CA3124127A1 (fr) * 2018-12-21 2020-06-25 Travere Therapeutics, Inc. Compositions de sparsentan amorphe
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
MX2022007471A (es) * 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
WO2022246200A1 (fr) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Méthodes de traitement de maladies ou de troubles rénaux
TW202328116A (zh) 2021-08-26 2023-07-16 大陸商上海翰森生物醫藥科技有限公司 含芳環類生物拮抗劑、其製備方法及應用
US20250051315A1 (en) * 2021-12-28 2025-02-13 Alchemedicine, Inc. Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition
WO2024073672A1 (fr) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Polythérapie avec du sparsentan et un inhibiteur de sglt2 pour le traitement de maladies ou de troubles rénaux
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
AU2024279669A1 (en) 2023-05-31 2025-12-11 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
WO2025064688A1 (fr) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan pour le traitement de la néphropathie à immunoglobulines a (igan)
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE416772T1 (de) * 1998-07-06 2008-12-15 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (fr) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
HUE049450T2 (hu) 2009-03-31 2020-09-28 Ligand Pharm Inc Endotelin és angiotenzin II receptor antagonista bifenilszulfonamid glomeruloszklerózis és IgA által kiváltott nefropátia kezelésére
WO2010135350A2 (fr) 2009-05-20 2010-11-25 Pharmacopeia, Llc Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
DK3126330T3 (en) * 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
KR102902972B1 (ko) 2018-10-04 2025-12-22 트래버르 테라퓨틱스, 인코포레이티드 Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물

Also Published As

Publication number Publication date
EP3525784A1 (fr) 2019-08-21
US20190262317A1 (en) 2019-08-29
KR20230066644A (ko) 2023-05-16
JP2022137245A (ja) 2022-09-21
US20200281901A1 (en) 2020-09-10
BR112019007576A2 (pt) 2019-07-02
CA3039819A1 (fr) 2018-04-19
KR20190077348A (ko) 2019-07-03
CN117085013A (zh) 2023-11-21
US20250325523A1 (en) 2025-10-23
US20210196688A1 (en) 2021-07-01
WO2018071784A1 (fr) 2018-04-19
AU2017341825B2 (en) 2023-06-01
CN110049764A (zh) 2019-07-23
CN116983302A (zh) 2023-11-03
AU2017341825A1 (en) 2019-04-11
CN114788823A (zh) 2022-07-26
AU2023219839A1 (en) 2023-09-07
JP2022141802A (ja) 2022-09-29
AU2025271121A1 (en) 2025-12-18
EP3525784B1 (fr) 2026-01-28
KR102528435B1 (ko) 2023-05-03
JP2019530713A (ja) 2019-10-24
US20250325522A1 (en) 2025-10-23
CN117017985A (zh) 2023-11-10
KR20220132030A (ko) 2022-09-29
US10864197B2 (en) 2020-12-15
JP2025060754A (ja) 2025-04-10
AU2023219839B2 (en) 2025-08-21
KR20240162167A (ko) 2024-11-14

Similar Documents

Publication Publication Date Title
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3691623A4 (fr) Composés de benzosulfonyle
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3720430A4 (fr) Composés benzocarbonyle
MA45192A (fr) Traitement d'association
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3388004A4 (fr) Instrument de traitement
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3852745A4 (fr) Composés destinés au traitement de certaines leucémies
EP3445750A4 (fr) Composés thérapeutiques
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3409744A4 (fr) Agent de traitement de surface
MA47820A (fr) Traitement de la glycogénose de type iii
EP3406336A4 (fr) Nanofeuille de type structure c ur-écorce
EP3431566A4 (fr) Agent de traitement de surface
IL262708B (en) Di-substituted pyrazole compounds for the treatment of diseases
EP3016944A4 (fr) Composés destinés au traitement de la mucosviscidose
EP3464336A4 (fr) Composés
IL282114A (en) Processes for preparing functionalized cyclooctenes
EP3371151A4 (fr) Composés destinés au traitement du cancer et épigénétique
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3416645A4 (fr) Composés pour le traitement du paludisme
EP3007722A4 (fr) Méthodes de traitement de l'hypotension
EP3270968C0 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
MA45552A (fr) Compositions destinées au traitement de l'amylose